Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL.

Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.

2.

A health dialogue intervention reduces cardiovascular risk factor levels: a population based randomised controlled trial in Swedish primary care setting with 1-year follow-up.

Hellstrand M, Simonsson B, Engström S, Nilsson KW, Molarius A.

BMC Public Health. 2017 Aug 22;17(1):669. doi: 10.1186/s12889-017-4670-4.

3.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

4.

Physical mobility, physical activity, and obesity among elderly: findings from a large population-based Swedish survey.

Asp M, Simonsson B, Larm P, Molarius A.

Public Health. 2017 Jun;147:84-91. doi: 10.1016/j.puhe.2017.01.032. Epub 2017 Mar 19.

PMID:
28404503
5.

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.

Söderlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Strömberg U, Loskog A.

Leuk Res. 2016 Nov;50:95-103. doi: 10.1016/j.leukres.2016.09.019. Epub 2016 Sep 27.

PMID:
27710869
6.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
7.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

8.

Erratum to: Psychosomatic complaints and sense of coherence among adolescents in a county in Sweden: a cross-sectional school survey.

Simonsson B, Nilsson KW, Leppert J, Diwan VK.

Biopsychosoc Med. 2015 Nov 6;9:22. doi: 10.1186/s13030-015-0050-4. eCollection 2015. No abstract available.

9.

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B.

Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. Epub 2015 Sep 29.

PMID:
26416462
10.

Epidemiology of chronic myeloid leukaemia: an update.

Höglund M, Sandin F, Simonsson B.

Ann Hematol. 2015 Apr;94 Suppl 2:S241-7. doi: 10.1007/s00277-015-2314-2. Epub 2015 Mar 27. Review.

PMID:
25814090
11.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R.

Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18.

PMID:
25783795
12.

Social inequalities in self-reported refraining from health care due to financial reasons in Sweden: health care on equal terms?

Molarius A, Simonsson B, Lindén-Boström M, Kalander-Blomqvist M, Feldman I, Eriksson HG.

BMC Health Serv Res. 2014 Nov 29;14:605. doi: 10.1186/s12913-014-0605-2.

13.

Socioeconomic differences in self-rated oral health and dental care utilisation after the dental care reform in 2008 in Sweden.

Molarius A, Engström S, Flink H, Simonsson B, Tegelberg A.

BMC Oral Health. 2014 Nov 18;14:134. doi: 10.1186/1472-6831-14-134.

14.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group.

Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.

15.

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K.

Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28.

PMID:
24372965
16.

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevärn B, Myhr-Eriksson K, Ohm L, Olsson-Strömberg U, Själander A, Wadenvik H, Simonsson B, Stenke L, Richter J.

Blood. 2013 Aug 15;122(7):1284-92. doi: 10.1182/blood-2013-04-495598. Epub 2013 Jul 10.

17.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.

Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Review.

18.

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Christiansson L, Söderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Strömberg U, Loskog AS.

PLoS One. 2013;8(1):e55818. doi: 10.1371/journal.pone.0055818. Epub 2013 Jan 31.

19.

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG).

Leukemia. 2013 Jul;27(7):1520-6. doi: 10.1038/leu.2013.19. Epub 2013 Jan 18.

PMID:
23328954
20.

Medical registries represent vital patient interests and should not be dismantled by stricter regulation.

Hansson MG, Simonsson B, Feltelius N, Forsberg JS, Hasford J.

Cancer Epidemiol. 2012 Dec;36(6):575-8. doi: 10.1016/j.canep.2012.06.009. Epub 2012 Jul 15.

PMID:
22796267
21.

Parental age, family size, and offspring's risk of childhood and adult acute leukemia.

Larfors G, Hallböök H, Simonsson B.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1185-90. doi: 10.1158/1055-9965.EPI-12-0178. Epub 2012 Apr 26.

22.

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.

Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R.

Blood. 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. Epub 2012 Apr 16.

PMID:
22508936
23.

The EUTOS CML score aims to support clinical decision-making.

Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.

Blood. 2012 Mar 22;119(12):2966-7. doi: 10.1182/blood-2012-01-402511. No abstract available.

PMID:
22442336
24.

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Själander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K; Nordic CML Study Group.

Blood. 2011 Sep 22;118(12):3228-35. doi: 10.1182/blood-2011-02-336685. Epub 2011 Jun 17.

PMID:
21685374
25.

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.

Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038. Epub 2011 May 2.

PMID:
21536864
26.

Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist CA, Christiansson LH, Thörn I, Mangsbo S, Paul-Wetterberg G, Sundström C, Tötterman TH, Simonsson B, Enblad G, Frisk P, Olsson-Strömberg U, Loskog AS.

Immunology. 2011 Jul;133(3):296-306. doi: 10.1111/j.1365-2567.2011.03439.x. Epub 2011 Apr 5.

27.

Interferon alpha for treatment of chronic myeloid leukemia.

Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K.

Curr Drug Targets. 2011 Mar 1;12(3):420-8. Review.

PMID:
21143150
28.

The European LeukemiaNet: achievements and perspectives.

Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet.

Haematologica. 2011 Jan;96(1):156-62. doi: 10.3324/haematol.2010.032979. Epub 2010 Nov 3.

29.

Second-generation BCR-ABL kinase inhibitors in CML.

Simonsson B, Porkka K, Richter J.

N Engl J Med. 2010 Oct 21;363(17):1673; author reply 1673-5. doi: 10.1056/NEJMc1007927. No abstract available.

PMID:
20973145
30.

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.

Olsson-Strömberg U, Hermansson M, Lundán T, Ohm AC, Engdahl I, Höglund M, Simonsson B, Porkka K, Barbany G.

Eur J Haematol. 2010 Nov;85(5):399-404. doi: 10.1111/j.1600-0609.2010.01506.x.

PMID:
20659155
31.

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.

Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Strömberg U, Loskog AS.

Immunology. 2010 Nov;131(3):371-6. doi: 10.1111/j.1365-2567.2010.03308.x.

32.

[More and more live longer than 65 years. Fewer smokers and more people with healthy hearts probable explanations].

Nilsson G, Simonsson B.

Lakartidningen. 2009 Nov 4-12;106(45):2956-7. Swedish. No abstract available.

PMID:
19998816
33.

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet.

J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2. Review.

34.

Sense of coherence and psychological well-being: improvement with age.

Nilsson KW, Leppert J, Simonsson B, Starrin B.

J Epidemiol Community Health. 2010 Apr;64(4):347-52. doi: 10.1136/jech.2008.081174. Epub 2009 Aug 19.

PMID:
19692734
35.

Estimated time for occurrence of smoking-related consequences among pregnant and non-pregnant women.

Ortendahl M, Uttermalm A, Simonsson B, Näsman P, Wallsten T.

Int J Environ Res Public Health. 2009 May;6(5):1665-75. doi: 10.3390/ijerph6051665. Epub 2009 May 15.

36.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K.

Leukemia. 2009 Aug;23(8):1398-405. doi: 10.1038/leu.2009.46. Epub 2009 Mar 19.

PMID:
19295545
37.

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B.

Blood. 2009 May 7;113(19):4497-504. doi: 10.1182/blood-2008-12-191254. Epub 2009 Mar 4.

PMID:
19264678
38.

Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.

Porkka K, Mustjoki S, Simonsson B.

Expert Rev Hematol. 2009 Feb;2(1):81-91. doi: 10.1586/17474086.2.1.81. Review.

PMID:
21082997
39.

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A.

Leukemia. 2008 Sep;22(9):1707-11. doi: 10.1038/leu.2008.156. Epub 2008 Jun 12.

PMID:
18548095
40.

Psychosomatic complaints and sense of coherence among adolescents in a county in Sweden: a cross-sectional school survey.

Simonsson B, Nilsson KW, Leppert J, Diwan VK.

Biopsychosoc Med. 2008 Feb 8;2:4. doi: 10.1186/1751-0759-2-4. Erratum in: Biopsychosoc Med. 2015;9:22.

41.

Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.

Gupta M, Milani L, Hermansson M, Simonsson B, Markevärn B, Syvänen AC, Barbany G.

Biochem Biophys Res Commun. 2008 Feb 15;366(3):848-51. Epub 2007 Dec 17.

PMID:
18082628
42.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S.

Blood. 2007 Oct 1;110(7):2309-15. Epub 2007 May 11.

PMID:
17496201
43.

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.

ESMO Guidelines Working Group, Simonsson B.

Ann Oncol. 2007 Apr;18 Suppl 2:ii51-2. No abstract available. Erratum in: Ann Oncol. 2008 May;19(5):1027-9.

PMID:
17491046
44.

Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients.

Hagberg A, Olsson-Strömberg U, Wickenberg-Bolin U, Göransson H, Isaksson A, Bengtsson M, Höglund M, Simonsson B, Barbany G.

Leuk Res. 2007 Jul;31(7):931-8. Epub 2007 Jan 4.

PMID:
17207527
45.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

46.

Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.

Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B.

Leuk Lymphoma. 2006 Sep;47(9):1768-73.

PMID:
17064986
47.

[Clinical research at the European LeukemiaNet].

Saussele S, Adam K, Hochhaus A, Béné MC, Büchner T, Burnett A, Finazzi G, Fonatsch C, Gluckman E, Gökbuget N, Grimwade DJ, Haferlach T, Hallek M, Hasford J, Hoelzer D, Ljungman P, Niederwieser D, Serve H, Simonsson B, de Witte TJ, Hehlmann R; European LeukemiaNet.

Dtsch Med Wochenschr. 2006 Oct 27;131(43):2423-6. German. No abstract available.

PMID:
17054061
48.

Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.

Olsson-Strömberg U, Aleskog A, Björnberg A, Höglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R, Lindhagen E.

Anticancer Drugs. 2006 Jul;17(6):631-9.

PMID:
16917208
49.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R; European LeukemiaNet.

Blood. 2006 Sep 15;108(6):1809-20. Epub 2006 May 18. Review.

PMID:
16709930
50.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K.

Blood. 2006 Jul 1;108(1):88-96. Epub 2006 Mar 23.

PMID:
16556892

Supplemental Content

Loading ...
Support Center